← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksDXCMPrice Target
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargets

DXCM logoDexCom, Inc. (DXCM) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026

Current Price
$60.36
Market reference
Price Target
$80.88
+34.0% Upside
Target Range
$67.00 — $100.00
Wide divergence
Analyst Rating
Buy
52 analysts
Forward P/E24.2x
Trailing P/E28.9x
Forward PEG2.31
Implied Growth+5.3%
Median Target$78.50
Analyst Spread40.8%

Analysts see +34.0% upside to their consensus target of $80.88. The bullish rating consensus aligns with positive price target gap.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$60.36
Consensus$80.88
High$100.00
Low$67.00
Bear Case
$67
+11.0%
Consensus
$81
+34.0%
Bull Case
$100
+65.7%

Analyst Ratings Distribution

Breakdown of 52 published analyst recommendations for DXCM

42/52 analysts are bullish
+39
BearishBullish
Weighted analyst sentiment score based on 52 ratings
ConsensusBuy
Coverage52 Analysts
Net Score+39
Bull / Bear81% / 4%
Strong Buy12%
Buy4179%
Hold815%
Sell24%
Strong Sell00%
Strong Buy
12%
Buy
4179%
Hold
815%
Sell
24%
Strong Sell
00%
Recommendation Mix81% Buy · 15% Hold · 4% Sell
Buy (42)Hold (8)Sell (2)

DXCM Price Target Analysis

Updated May 7, 2026

As of May 7, 2026, DexCom, Inc. (DXCM) has a Wall Street consensus price target of $80.88, based on estimates from 52 covering analysts. With the stock currently trading at $60.36, this represents a potential upside of +34.0%. The company has a market capitalization of $23.29B.

Analyst price targets range from a low of $67.00 to a high of $100.00, representing a 41% spread in expectations. The median target of $78.50 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 42 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 2 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, DXCM trades at a trailing P/E of 28.9x and forward P/E of 24.2x. The forward PEG ratio of 2.31 reflects a premium valuation. Analysts expect EPS to grow +5.3% over the next year.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+62.4%
Avg Forward P/E15.4x
Peers with Coverage9 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
ABT logoABTAbbott Laboratories$150.0B$86.25$128.71+49.2%Buy15.7x41
PODD logoPODDInsulet Corporation$10.6B$151.17$339.00+124.3%Buy23.8x50
TNDM logoTNDMTandem Diabetes Care, Inc.$1.2B$18.03$31.62+75.4%Buy—39
NVCR logoNVCRNovoCure Limited$1.9B$16.50$33.50+103.1%Buy—15
INVA logoINVAInnoviva, Inc.$1.9B$22.52$37.67+67.3%Buy11.8x10
MDT logoMDTMedtronic plc$99.5B$77.60$109.50+41.1%Buy14.1x49
PHG logoPHGKoninklijke Philips N.V.$25.9B$27.23——Hold17.6x22
ITGR logoITGRInteger Holdings Corporation$3.0B$86.29$98.00+13.6%Buy13.3x14
SENS logoSENSSenseonics Holdings, Inc.$221M$5.36$9.00+67.9%Buy—16
BDX logoBDXBecton, Dickinson and Company$52.4B$144.76$172.85+19.4%Buy11.6x33

Upside Potential Comparison

PODD logoPODD
+124.3%
NVCR logoNVCR
+103.1%
TNDM logoTNDM
+75.4%
SENS logoSENS
+67.9%
INVA logoINVA
+67.3%
ABT logoABT
+49.2%
MDT logoMDT
+41.1%
BDX logoBDX
+19.4%

Full DXCM Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

See DXCM's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is DXCM Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare DXCM vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

DXCM — Frequently Asked Questions

Quick answers to the most common questions about buying DXCM stock.

What is the DXCM stock price target for 2026?

The consensus Wall Street price target for DXCM is $80.88, representing 34.0% upside from the current price of $60.36. With 52 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is DXCM a buy, sell, or hold?

DXCM has a consensus rating of "Buy" based on 52 Wall Street analysts. The rating breakdown is predominantly bullish, with 42 Buy/Strong Buy ratings. The consensus 12-month price target of $80.88 implies 34.0% upside from current levels.

Is DXCM stock overvalued or undervalued?

DXCM trades at a forward P/E of 24.2478x, representing a moderate valuation. With analysts targeting $80.88 (34.0% implied move), the stock appears reasonably valued with upside.

How high can DXCM stock go?

The most bullish Wall Street analyst has a price target of $100 for DXCM, while the most conservative target is $67. The consensus of $80.88 represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover DXCM stock?

DXCM is heavily covered by Wall Street, with 52 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 41 have Buy ratings, 8 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the DXCM stock forecast?

The 12-month DXCM stock forecast based on 52 Wall Street analysts shows a consensus price target of $80.88, with estimates ranging from $67 (bear case) to $100 (bull case). The median consensus rating is "Buy".

What is DXCM's forward P/E ratio?

DXCM trades at a forward P/E ratio of 24.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 28.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy DXCM stock?

Wall Street analysts are very optimistic on DXCM, with a "Buy" consensus rating and $80.88 price target (34.0% upside). 42 of 52 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do DXCM price targets vary so much?

DXCM analyst price targets range from $67 to $100, a 41% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $80.88 consensus represents the middle ground.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.